Introduction
Cystic fibrosis (CF) is the most common lethal inherited condition affecting the Caucasian population. Clinical characteristics are caused by the absence or reduction of cystic fibrosis transmembrane conductance regulator (CFTR) protein function, which perturbs ion channels at the apical membrane of epithelial cells and results in a multisystem disease. Disease of the lower airways is considered the most important manifestation as it is the cause of morbidity and mortality in a large percentage of people [1] .
Lower airway disease is secondary to chronic bacterial infection and a dysregulated host inflammatory response that is dominated by neutrophils [2] .
Currently, a limited range of bacteria which cause lower airway infection, including Staphylococcus aureus, Haemophilus influenzae, Pseudomonas aeruginosa and Burkholderia cepacia complex, have been correlated with worse outcomes of people with CF ( Figure 1) [3] ; therefore, they are recognised as CF pathogens and are usually targeted by antibiotic treatment regimens [4] . These pathogens are routinely detected using aerobic culturebased methods [5] ; however, such methods fail to culture obligate anaerobic bacteria whilst non-target facultative anaerobic microorganisms isolated are often considered "oropharyngeal flora".
During the past decade, unexpected bacterial community richness (number of species) within the CF lower airways has been demonstrated [6] [7] [8] [9] [10] [11] [12] .
Furthermore, anoxic niches are known to exist within CF sputum, which supports the survival of anaerobic bacteria in the lower airways [13, 14] . Many anaerobic species detected in CF respiratory samples are also present in the microbiota of the oral cavity and in a recent study, periodontal-associated 4 anaerobic bacteria were found in plaque and sputum samples of some people with CF [15*]. Therefore, detection of oral-associated bacteria in the lungs may be attributed to migration from the oral cavity to the lower airways [16] [17] [18] .
Despite the accumulating knowledge of the range and abundance of bacteria in the diverse, dynamic and spatially heterogeneous lower airway communities, the contribution of obligate and non-target facultative anaerobic bacteria (henceforth referred to collectively as "anaerobic bacteria") to the pathogenesis of CF lower airway disease is currently not well understood. In fact, there remains much deliberation about whether anaerobic bacteria are pathogenic in the CF lower airways, commensals with negligible clinical impact or members of a "normal" airway microbiota. This review focuses on the most recent knowledge pertaining to the potential role of anaerobes detected within the polymicrobial communities of the CF lungs.
Potential pathophysiological role of anaerobic bacteria in chronic lower airway infection
Ecological analyses generally describe that a reduced bacterial diversity, including decreased richness of anaerobes, leads to dominance of a recognised pathogen and is associated with antibiotic use, increasing age and poorer lung function [19] [20] [21] [22] . Furthermore, it has been hypothesied that certain anaerobic bacteria potentially form part of a normal airway microbiota; the most frequently identified anaerobic genera (Prevotella, 83%; Veillonella, 54%) in CF sputum were also commonly detected in induced sputum of healthy controls [23*].
Variation in the abundance of anaerobic bacteria: impact on clinical status
It was recently shown that worse lung function (measured by lung clearance index) and increased inflammation (measured by blood C-Reactive Protein)
were associated with a lower total load of anaerobic bacteria in clinically stable people with CF ( Figure 2 
Genetic adaptation and antimicrobial resistance
It is evident that anaerobic bacteria persist in the CF lower airway community, even under continuous antibiotic pressure targeting recognised pathogens [31] . In order to become established members of a bacterial community, bacteria may undergo genetic adaptation to a specific niche. For example, various clonal lineages of P. aeruginosa are known to accumulate mutations in genes that enable adaptation of the bacterium to the dynamic CF airways including mutations that increase resistance to antibiotics or affect virulence traits (described as "pathoadaptation") [32] . Anaerobes from the CF lower airways are also more resistant to antibiotics when compared to similar anaerobic genera from the airways of healthy control subjects [33, 34] .
Therefore, this may indicate that anaerobic bacteria are established members of the lower airway community and are undergoing adaptation to antibiotic selective pressure within the lungs. Some strains of P. aeruginosa are associated with worse patient outcomes and similar patterns have been reported for periodontal microorganisms where differences in pathogenicity are observed between strains of the same species [35, 36] . Therefore, further work is warranted to investigate genetic adaptations and diversity of particular anaerobic species in the CF lower airway environment.
Potential virulence mechanisms
Anaerobic bacteria are normal commensals but are also considered opportunistic pathogens, often involved in polymicrobial infections. Therefore, it is plausible that anaerobic bacteria could constitute members of the normal microbiota in health but also conceivable that they could contribute to the pathogenesis of chronic lung disease in people with CF via direct or indirect mechanisms. Recent evidence from a number of studies demonstrate that anaerobes may cause a host inflammatory response, interact synergistically with recognised CF pathogens and protect recognised pathogens from antibiotics by enhanced antimicrobial resistance ( Figure 3 ). 
Inflammation of the lower airways

Interaction with other microorganisms in polymicrobial communities
Anaerobic bacteria may influence the progression of CF lower airway disease by inter-species interactions that enhance the pathogenicity or colonisation ability of recognised pathogens within the lower airways. In fact, it was previously hypothesised that certain anaerobes might create a favourable microenvironment for recognised CF pathogens to colonise, cause infection and subsequently dominate the lower airways ( Figure 2 isolates may increase the virulence of obligate anaerobes. A study found that increased mortality was observed when mice were intra-tracheally inoculated with Porphyromonas gingivalis and a dose of pyocyanin at a concentration found in the CF airways compared to the anaerobe alone [40] .
Biofilm formation is a feature of chronic airway infection in CF and it was shown that P. aeruginosa grows as a mixed biofilm in vitro with various Furthermore, in patients with bronchiectasis it was reported that detection of non-tuberculous mycobacteria (NTM) in BAL samples was associated with a higher prevalence of Prevotella species compared to non-NTM infected patients [43] . Therefore, Prevotella species may affect colonisation of NTM in chronic lung infections.
Enhanced antibiotic resistance
A high proportion of CF-associated Prevotella species were previously shown to produce β-lactamases [33] . In polymicrobial infections, β-lactamaseproducing bacteria may protect themselves and other members of the community from antimicrobial agents (the concept of "passive resistance") [44] . A recent study found that a β-lactamase-producing Prevotella species was able to shield P. aeruginosa from the activity of ceftazidime in vitro, which is used to target the pathogen during treatment of pulmonary exacerbations [45*]. Therefore, enabling P. aeruginosa to persist in the presence of ceftazidime may be an indirect method by which Prevotella species contribute to disease pathogenesis.
Should anaerobes be targeted by treatment?
There is currently a lack of evidence to conclude if anaerobic bacteria should be targeted when treating CF lower airway infection. Targeted treatment of bacteria, residing within the lungs, is also challenging with the types and formulations of antibiotics that are currently available. Anaerobic bacteria are generally susceptible to some broad-spectrum antibiotics that are routinely used in the management of CF lower airway infection (e.g. meropenem, piperacillin/tazobactam) [33] ; therefore, it is likely that anaerobes are nonspecifically targeted when recognised CF pathogens are treated.
Furthermore, systemic antibiotics may adversely affect anaerobic bacteria that are present in high abundance in the normal microbiota of the gastrointestinal tract and contribute to disruption of the intestinal microbial community ("dysbiosis") [46] . CF is characterised by both local and systemic inflammation and evidence is accumulating that indicates a relationship exists between the gut microbiota and the health of the airways [47] [48] [49] [50] . For example, disruption of gut homeostasis may result in immunoregulatory effects outside the intestinal tract, which may impact respiratory diseases including chronic obstructive pulmonary disease [51] . Therefore, any potential antibiotic treatment used to target anaerobes within the CF lower airways may need to be tailored to minimise adverse effects on the gut microbiota. Development of local therapies that specifically reduce bacterial interactions, limit the host inflammatory response triggered by anaerobes or minimise growth of target anaerobes in the lungs, e.g. hyperbaric oxygen therapy, may offer an alternative [27**,37**].
Metagenomic sequencing studies generally indicate that in the absence of anaerobes, the health of patients is worse. Studies are required to understand the activities and interactions of microbes in early-stage disease and how the evolution of the bacterial community towards a less diverse end-stage disease (as found in explanted lungs) can be prevented [52] . We have also entered the era of CFTR modulators (e.g. correctors and potentiators), which target CFTR dysfunction, and how these treatments affect development of the airway community has been under short-term surveillance [28, 53, 54] but longer studies are required. Furthermore, the members and functional characteristics of the airway microbiota are individual to a person. Based on analysis of lung tissue samples from a symptomatic paediatric CF patient, who underwent a right lower lobectomy [55, 56] , bacterial communities are also known to be spatially heterogeneous in non-end stage disease.
Therefore, virulence of anaerobic bacteria may differ both within and between people with CF.
In the future it may be possible to commence a personalised treatment approach that will maintain a normal microbial community, limit pathoadaptation of bacteria residing within the lower airways, prevent (Word count: 2312)
Key points
• Anaerobic bacteria are commonly detected in the lower airways of people with CF but their clinical significance is unknown.
• The relative abundance of anaerobes in the lower airways fluctuates over time.
• A lower abundance of anaerobes has been associated with worse lung function suggesting that anaerobes may form part of a normal airway community.
• Anaerobic bacteria produce virulence factors and may enhance pathogenicity and colonisation by recognised CF pathogens.
• A personalised treatment approach might be required to prevent the development of a microbiota that is characteristic of end-stage lung disease. (Reproduced with permission from the UK Cystic Fibrosis Trust). shield recognised cystic fibrosis pathogens from treatment with antibiotics.
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